Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
April 21, 2014
Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lines
March 31, 2014
Revance Therapeutics Added to Russell 2000(R) and 3000(R) Indexes
March 26, 2014
Revance Therapeutics Releases Fourth Quarter and Full Year 2013 Financial Results and Provides 2014 Outlook
March 12, 2014
Revance Therapeutics to Release Fourth Quarter and Full Year 2013 Financial Results and Host Conference Call on Wednesday, March 26, 2014
March 5, 2014
Revance to Add Angus C. Russell as Chairman to Its Board of Directors
February 19, 2014
Revance Therapeutics, Inc. Announces Participation in Cowen 34th Annual Health Care Conference
February 11, 2014
Revance Therapeutics, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Over-Allotment Option
February 5, 2014
Revance Therapeutics Announces Pricing of Initial Public Offering
April 2, 2013
Revance Therapeutics Announces $33 Million Series E Financing
March 25, 2013
Revance Therapeutics Announces Appointment of Lauren Silvernail as Chief Financial Officer
Displaying 261 - 270 of 277